Endologix Stock Price, News & Analysis (NASDAQ:ELGX)

$4.38 +0.05 (+1.15 %)
(As of 02/22/2018 09:42 AM ET)
Previous Close$4.38
Today's Range$4.24 - $4.49
52-Week Range$3.75 - $7.66
Volume598,800 shs
Average Volume770,385 shs
Market Capitalization$361.36 million
P/E Ratio-4.71
Dividend YieldN/A
Beta0.42

About Endologix (NASDAQ:ELGX)

Endologix logoEndologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Debt-to-Equity Ratio2.61%
Current Ratio2.90%
Quick Ratio2.11%

Price-To-Earnings

Trailing P/E Ratio-4.70962677820669
Forward P/E Ratio-7.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$192.93 million
Price / Sales1.89
Cash FlowN/A
Price / CashN/A
Book Value$1.36 per share
Price / Book3.22

Profitability

Trailing EPS($0.93)
Net Income$-154,670,000.00
Net Margins-41.60%
Return on Equity-52.18%
Return on Assets-13.70%

Miscellaneous

Employees782
Outstanding Shares83,450,000

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) issued its quarterly earnings data on Tuesday, February, 20th. The medical instruments supplier reported ($0.08) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.12. The medical instruments supplier had revenue of $44 million for the quarter, compared to the consensus estimate of $44.91 million. Endologix had a negative return on equity of 52.18% and a negative net margin of 41.60%. The firm's revenue was down 7.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.30) EPS. View Endologix's Earnings History.

Where is Endologix's stock going? Where will Endologix's stock price be in 2018?

9 brokerages have issued 1 year price objectives for Endologix's shares. Their forecasts range from $4.00 to $7.00. On average, they expect Endologix's share price to reach $5.36 in the next year. View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:

  • 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (1/30/2018)
  • 2. Canaccord Genuity analysts commented, "Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of." (8/4/2017)

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:

  • Daniel T. Lemaitre, Chairman of the Board (Age 63)
  • John D. McDermott, Chief Executive Officer, Director (Age 57)
  • Vaseem Mahboob, Chief Financial Officer, Corporate Secretary (Age 48)
  • John Onopchenko, Chief Operating Officer (Age 59)
  • Michael V. Chobotov Ph.D., Chief Technology Officer (Age 56)
  • Greg Morrow, Chief Marketing Officer
  • David M. Jennings, Vice President - Human Resources (Age 62)
  • Amanda L. DePalma, Vice President - Global Marketing (Age 45)
  • Meredith O. Huetter, Vice President - Global Medical Affairs (Age 43)
  • Michael P. Maszy, Vice President - Manufacturing (Age 40)

Who owns Endologix stock?

Endologix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (11.85%), Redmile Group LLC (7.10%), BlackRock Inc. (6.10%), Senzar Asset Management LLC (2.63%), Lombard Odier Asset Management USA Corp (1.86%) and Geode Capital Management LLC (0.86%). Company insiders that own Endologix stock include Amanda L Depalma, Dan Lemaitre, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Who sold Endologix stock? Who is selling Endologix stock?

Endologix's stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Goldman Sachs Group Inc., Cortina Asset Management LLC, C WorldWide Group Holding A S, Lombard Odier Asset Management USA Corp, Metropolitan Life Insurance Co. NY, Two Sigma Investments LP and Millennium Management LLC. View Insider Buying and Selling for Endologix.

Who bought Endologix stock? Who is buying Endologix stock?

Endologix's stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, ArrowMark Colorado Holdings LLC, Prosight Management LP, Millrace Asset Group Inc., Deutsche Bank AG, GW&K Investment Management LLC, BlackRock Inc. and MetLife Investment Advisors LLC. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy Endologix stock?

Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of Endologix stock can currently be purchased for approximately $4.38.

How big of a company is Endologix?

Endologix has a market capitalization of $361.36 million and generates $192.93 million in revenue each year. The medical instruments supplier earns $-154,670,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Endologix employs 782 workers across the globe.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (ELGX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  658
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endologix (NASDAQ:ELGX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.36$5.36$6.17$6.33
Price Target Upside: 0.13% upside0.13% upside27.54% upside45.59% upside

Endologix (NASDAQ:ELGX) Consensus Price Target History

Price Target History for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ:ELGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/2/2018JPMorgan Chase & Co.DowngradeNeutral -> UnderweightHighView Rating Details
12/12/2017Piper Jaffray CompaniesReiterated RatingOverweight -> OverweightHighView Rating Details
11/8/2017Canaccord GenuityReiterated RatingHold$5.00N/AView Rating Details
11/8/2017Stifel NicolausLower Price TargetHold$6.00 -> $5.50N/AView Rating Details
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
8/3/2017OppenheimerSet Price TargetHold$5.00HighView Rating Details
5/18/2017BMO Capital MarketsReiterated RatingHold$5.00HighView Rating Details
5/18/2017StephensDowngradeOverweight -> Equal Weight$6.00HighView Rating Details
5/18/2017BTIG ResearchDowngradeBuy -> Neutral$7.00HighView Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00N/AView Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
2/22/2016Credit Suisse GroupLower Price TargetOutperform$16.00 -> $10.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Endologix (NASDAQ:ELGX) Earnings History and Estimates Chart

Earnings by Quarter for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ ELGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018Q4 2017($0.20)($0.08)$44.91 million$44.00 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.17)($0.11)$47.21 million$45.99 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.18)($0.10)$47.58 million$48.60 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.24)($0.18)$41.15 million$42.60 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewListenView Earnings Details
11/1/2016Q316($0.15)($0.11)$51.83 million$52.12 millionViewN/AView Earnings Details
8/2/2016Q2($0.20)($0.20)$46.30 million$51.00 millionViewListenView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.08)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
7/21/2011Q2 2011($0.07)($0.09)ViewN/AView Earnings Details
4/21/2011Q1 2011($0.06)($0.09)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.01)($0.01)ViewN/AView Earnings Details
7/22/2010Q2 2010($0.01)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.01)($0.01)ViewN/AView Earnings Details
7/22/2009Q2 2009($0.02)($0.01)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.03)($0.03)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.06)($0.04)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.07)($0.07)ViewN/AView Earnings Details
7/24/2008Q2 2008($0.06)($0.09)ViewN/AView Earnings Details
4/24/2008Q1 2008($0.07)($0.09)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.08)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Endologix (NASDAQ:ELGX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.16)($0.16)($0.16)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Endologix (NASDAQ:ELGX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Endologix (NASDAQ ELGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ ELGX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2017Dan LemaitreDirectorBuy22,522$4.43$99,772.4668,689View SEC Filing  
5/19/2017Guido J NeelsDirectorBuy20,000$4.32$86,400.0061,380View SEC Filing  
5/19/2017Robert D MitchellPresidentBuy2,200$4.32$9,504.00315,699View SEC Filing  
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00657,608View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.0041,574View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00108,511View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.0041,380View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.8042,594View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00189,269View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.0027,728View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.9544,461View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80663,624View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35158,804View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70318,233View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.0039,243View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.6045,037View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.0088,106View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00569,825View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.8024,825View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00126,080View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00309,890View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.3433,648View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00348,245View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.6050,899View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endologix (NASDAQ ELGX) News Headlines

Source:
DateHeadline
John McDermott Steps Down as Endologix (ELGX) CEOJohn McDermott Steps Down as Endologix (ELGX) CEO
www.streetinsider.com - February 22 at 8:59 AM
Endologix reports 4Q lossEndologix reports 4Q loss
finance.yahoo.com - February 22 at 8:59 AM
Endologix (ELGX) Issues  Earnings ResultsEndologix (ELGX) Issues Earnings Results
www.americanbankingnews.com - February 21 at 9:30 PM
Endologix Q4 Earnings PreviewEndologix Q4 Earnings Preview
finance.yahoo.com - February 21 at 4:56 PM
Zacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.20 MillionZacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.20 Million
www.americanbankingnews.com - February 16 at 4:06 AM
-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - February 14 at 3:10 PM
Endologix (ELGX) Set to Announce Quarterly Earnings on TuesdayEndologix (ELGX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 13 at 2:56 AM
Endologix, Inc. (ELGX) Receives Consensus Recommendation of "Hold" from BrokeragesEndologix, Inc. (ELGX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 1:22 AM
Endologix (ELGX) Upgraded at BidaskClubEndologix (ELGX) Upgraded at BidaskClub
www.americanbankingnews.com - February 10 at 12:14 PM
Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Endologix, Glaukos, and Mazor RoboticsQuotidian Technical Highlights on Selected Medical Supplies Stocks -- Endologix, Glaukos, and Mazor Robotics
www.prnewswire.com - February 7 at 6:34 AM
Endologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical StudyEndologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical Study
finance.yahoo.com - February 5 at 9:22 AM
Endologix (ELGX) Cut to Sell at Zacks Investment ResearchEndologix (ELGX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - January 30 at 9:42 PM
Endologix, Inc. to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceEndologix, Inc. to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 30 at 4:13 PM
$45.20 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter$45.20 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - January 30 at 2:50 AM
Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - January 29 at 9:36 AM
Zacks: Brokerages Expect Endologix, Inc. (ELGX) to Announce -$0.22 Earnings Per ShareZacks: Brokerages Expect Endologix, Inc. (ELGX) to Announce -$0.22 Earnings Per Share
www.americanbankingnews.com - January 28 at 3:16 PM
Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on February 21, 2018Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on February 21, 2018
finance.yahoo.com - January 25 at 4:12 PM
Endologix (ELGX) Downgraded to "Sell" at BidaskClubEndologix (ELGX) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - January 21 at 3:34 PM
At $4.27, Is It Time To Buy Endologix Inc (NASDAQ:ELGX)?At $4.27, Is It Time To Buy Endologix Inc (NASDAQ:ELGX)?
finance.yahoo.com - January 19 at 5:54 PM
Endologix, Inc. (ELGX) Receives Consensus Recommendation of "Hold" from AnalystsEndologix, Inc. (ELGX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 1:32 AM
Zacks: Brokerages Anticipate Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.20 MillionZacks: Brokerages Anticipate Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.20 Million
www.americanbankingnews.com - January 13 at 10:50 AM
 Analysts Anticipate Endologix, Inc. (ELGX) to Post -$0.22 Earnings Per Share Analysts Anticipate Endologix, Inc. (ELGX) to Post -$0.22 Earnings Per Share
www.americanbankingnews.com - January 11 at 5:22 PM
Form 8-K ENDOLOGIX INC /DE/ For: Jan 05Form 8-K ENDOLOGIX INC /DE/ For: Jan 05
www.streetinsider.com - January 9 at 9:29 AM
Does Endologix Inc’s (NASDAQ:ELGX) Earnings Growth Make It An Outperformer?Does Endologix Inc’s (NASDAQ:ELGX) Earnings Growth Make It An Outperformer?
finance.yahoo.com - January 4 at 5:22 PM
JPMorgan Diagnoses The MedTech Space: Stock Picks And PansJPMorgan Diagnoses The MedTech Space: Stock Picks And Pans
finance.yahoo.com - January 2 at 6:47 PM
Endologix, Inc. breached its 50 day moving average in a Bullish Manner : ELGX-US : January 1, 2018Endologix, Inc. breached its 50 day moving average in a Bullish Manner : ELGX-US : January 1, 2018
finance.yahoo.com - January 1 at 9:25 AM
Endologix, Inc. (ELGX)Endologix, Inc. (ELGX)
finance.yahoo.com - December 30 at 9:20 AM
$45.37 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter$45.37 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - December 28 at 8:32 PM
Critical Analysis: Orthopediatrics (KIDS) and Endologix (ELGX)Critical Analysis: Orthopediatrics (KIDS) and Endologix (ELGX)
www.americanbankingnews.com - December 27 at 9:06 PM
Critical Contrast: Endologix (ELGX) and Its CompetitorsCritical Contrast: Endologix (ELGX) and Its Competitors
www.americanbankingnews.com - December 19 at 5:22 PM
Endologix, Inc. to Present at the J.P. Morgan Healthcare ConferenceEndologix, Inc. to Present at the J.P. Morgan Healthcare Conference
finance.yahoo.com - December 19 at 5:21 PM
Critical Comparison: Endologix (ELGX) vs. Its RivalsCritical Comparison: Endologix (ELGX) vs. Its Rivals
www.americanbankingnews.com - December 19 at 9:32 AM
Reviewing Endologix (ELGX) & The CompetitionReviewing Endologix (ELGX) & The Competition
www.americanbankingnews.com - December 19 at 3:16 AM
Contrasting Endologix (ELGX) & Its PeersContrasting Endologix (ELGX) & Its Peers
www.americanbankingnews.com - December 18 at 7:22 PM
Endologix (ELGX) & Its Competitors Head-To-Head SurveyEndologix (ELGX) & Its Competitors Head-To-Head Survey
www.americanbankingnews.com - December 18 at 7:22 PM
Head to Head Review: Endologix (ELGX) versus Its RivalsHead to Head Review: Endologix (ELGX) versus Its Rivals
www.americanbankingnews.com - December 17 at 11:36 PM
Endologix (ELGX) versus The Competition Head to Head SurveyEndologix (ELGX) versus The Competition Head to Head Survey
www.americanbankingnews.com - December 17 at 9:28 PM
Endologix (ELGX) Downgraded to "Hold" at BidaskClubEndologix (ELGX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - December 16 at 2:52 PM
ENDOLOGIX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ... - PR Newswire (press release)ENDOLOGIX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ... - PR Newswire (press release)
www.prnewswire.com - December 16 at 9:28 AM
Contrasting Endologix (ELGX) and The CompetitionContrasting Endologix (ELGX) and The Competition
www.americanbankingnews.com - December 15 at 3:30 PM
Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : December 15, 2017Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : December 15, 2017
finance.yahoo.com - December 15 at 9:51 AM
Analyzing Endologix (ELGX) & Its RivalsAnalyzing Endologix (ELGX) & Its Rivals
www.americanbankingnews.com - December 14 at 11:04 PM
Endologix (ELGX) vs. Its Peers Critical ContrastEndologix (ELGX) vs. Its Peers Critical Contrast
www.americanbankingnews.com - December 14 at 7:50 PM
Financial Comparison: Endologix (ELGX) vs. The CompetitionFinancial Comparison: Endologix (ELGX) vs. The Competition
www.americanbankingnews.com - December 14 at 5:30 AM
Reviewing Endologix (ELGX) & Its CompetitorsReviewing Endologix (ELGX) & Its Competitors
www.americanbankingnews.com - December 13 at 11:16 AM
Head-To-Head Contrast: Endologix (ELGX) and Its RivalsHead-To-Head Contrast: Endologix (ELGX) and Its Rivals
www.americanbankingnews.com - December 12 at 5:16 PM
Endologix (ELGX) Now Covered by Piper Jaffray CompaniesEndologix (ELGX) Now Covered by Piper Jaffray Companies
www.americanbankingnews.com - December 12 at 11:28 AM
Analyzing Endologix (ELGX) & The CompetitionAnalyzing Endologix (ELGX) & The Competition
www.americanbankingnews.com - December 12 at 7:57 AM
Financial Review: Endologix (ELGX) versus Its RivalsFinancial Review: Endologix (ELGX) versus Its Rivals
www.americanbankingnews.com - December 11 at 11:22 PM
Critical Comparison: Endologix (ELGX) vs. Its PeersCritical Comparison: Endologix (ELGX) vs. Its Peers
www.americanbankingnews.com - December 11 at 7:16 PM

SEC Filings

Endologix (NASDAQ:ELGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endologix (NASDAQ:ELGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endologix (NASDAQ ELGX) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.